⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
businesswire.com
JNJ
Elias World Media Celebrates 10 Years of Excellence With Multiple Telly Awards and CEO Recognition, and Announces Growth and Expansion Plans for 2026
businesswire.com
MSFT
PG
JNJ
ALGN
DE
Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson
businesswire.com
JNJ
Digital Manufacturing in Life Sciences Market to Reach USD 177.5 Billion by 2035, Leading at 15.6% CAGR by 2035
globenewswire.com
AZN
SI
HON
AMZN
PFE
NVS
JNJ
GEHC
CAR
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
globenewswire.com
JNJ
Los Angeles Jury Delivers $40 Million Verdict Against Johnson & Johnson in Talcum Powder Ovarian Cancer Trial
prnewswire.com
JNJ
Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson, Pfizer, Biocon, Intas Pharmaceuticals, Viatris and More - ResearchAndMarkets.com
businesswire.com
AMGN
JNJ
PFE
VTRS
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
prnewswire.com
JNJ
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
prnewswire.com
JNJ
Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight
prnewswire.com
ABBV
JNJ
LLY
MRK
PFE
ABVX